HHS is creating a new pathway to evaluate which conditions should be added to the national newborn screening panel as part of a broader effort to modernize a review process that officials say has lagged behind advances in genetic medicine.
The Health Resources and Services Administration on Aug. 11 launched a framework to streamline evidence reviews for the Recommended Uniform Screening Panel, the federal guideline nearly all state newborn screening programs follow.
A Federal Register notice published Aug. 12 laid out the mechanism: a National Newborn Screening Stakeholder Workgroup funded through a $700,000 award to the Silver Spring, Md.-based Association of Public Health Laboratories.
The workgroup will assess candidate conditions and take on emerging issues such as genomic sequencing and data collection. It will include representatives from state screening programs, families, clinicians, researchers and laboratorians, meet at least three times a year and be open to the public. HRSA said it will continue commissioning independent evidence reviews before recommendations reach the HHS secretary, who retains final authority over the panel.
The workgroup’s project period runs through June 2028. HRSA said membership opportunities and meeting agendas will be announced publicly.
States and territories screen more than 3.6 million infants each year and identify about 12,900 with heritable conditions, according to HRSA. The RUSP includes 40 core conditions and 26 secondary conditions; as of May 2026, 85% of programs screened for 35 of them.
The overhaul lands amid a wider federal push on newborn and maternal health. On Aug. 12, HHS launched a $4 million initiative to expand rapid, point-of-care syphilis testing for women in emergency departments and other nontraditional settings, with about $3.25 million flowing to the CDC’s Division of STD Prevention through February 2027.
Congenital syphilis cases reached about 4,000 in 2024 — a roughly 700% increase over the past decade — and the condition was tied to 279 stillbirths and infant deaths in 2023, according to HHS. Newborn syphilis rates have risen for more than a decade, and HHS said 83% of 2023 cases could have been prevented with timely testing and treatment.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
